WO2023137399A3 - Inflammatory disease treatment using anti-tissue factor antibodies - Google Patents

Inflammatory disease treatment using anti-tissue factor antibodies Download PDF

Info

Publication number
WO2023137399A3
WO2023137399A3 PCT/US2023/060589 US2023060589W WO2023137399A3 WO 2023137399 A3 WO2023137399 A3 WO 2023137399A3 US 2023060589 W US2023060589 W US 2023060589W WO 2023137399 A3 WO2023137399 A3 WO 2023137399A3
Authority
WO
WIPO (PCT)
Prior art keywords
tissue factor
inflammatory disease
disease treatment
factor antibodies
antibodies
Prior art date
Application number
PCT/US2023/060589
Other languages
French (fr)
Other versions
WO2023137399A2 (en
Inventor
Thi-Sau Migone
William Greene
Original Assignee
Iconic Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Llc filed Critical Iconic Therapeutics Llc
Publication of WO2023137399A2 publication Critical patent/WO2023137399A2/en
Publication of WO2023137399A3 publication Critical patent/WO2023137399A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs for treatment of inflammatory diseases. Also provided herein are methods of treating subjects having inflammatory diseases by administering the anti-TF antibodies or ADCs.
PCT/US2023/060589 2022-01-12 2023-01-12 Inflammatory disease treatment using anti-tissue factor antibodies WO2023137399A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263298991P 2022-01-12 2022-01-12
US63/298,991 2022-01-12

Publications (2)

Publication Number Publication Date
WO2023137399A2 WO2023137399A2 (en) 2023-07-20
WO2023137399A3 true WO2023137399A3 (en) 2023-09-14

Family

ID=87278501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/060589 WO2023137399A2 (en) 2022-01-12 2023-01-12 Inflammatory disease treatment using anti-tissue factor antibodies

Country Status (2)

Country Link
TW (1) TW202342517A (en)
WO (1) WO2023137399A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311034A1 (en) * 2007-04-30 2008-12-18 Anderson Glenn M Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
US20190169311A1 (en) * 2008-12-09 2019-06-06 Genmab A/S Human Antibodies Against Tissue Factor and Methods of Use Thereof
WO2021003399A1 (en) * 2019-07-03 2021-01-07 Iconic Therapeutics, Inc. Anti-tissue factor antibody-drug conjugates and related methods
WO2022011324A1 (en) * 2020-07-10 2022-01-13 Iconic Therapeutics, Inc. Inflammatory disease treatment using anti-tissue factor antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080311034A1 (en) * 2007-04-30 2008-12-18 Anderson Glenn M Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
US20190169311A1 (en) * 2008-12-09 2019-06-06 Genmab A/S Human Antibodies Against Tissue Factor and Methods of Use Thereof
WO2021003399A1 (en) * 2019-07-03 2021-01-07 Iconic Therapeutics, Inc. Anti-tissue factor antibody-drug conjugates and related methods
WO2022011324A1 (en) * 2020-07-10 2022-01-13 Iconic Therapeutics, Inc. Inflammatory disease treatment using anti-tissue factor antibodies

Also Published As

Publication number Publication date
TW202342517A (en) 2023-11-01
WO2023137399A2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CL2023000099A1 (en) Inflammatory disease treatment using anti-tissue factor antibodies
EP1140170A4 (en) Novel agents and methods for treatment and diagnosis of ocular disorders
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2007075270A3 (en) Multivalent immunoglobulin-based bioactive assemblies
MX2021015974A (en) Anti-tissue factor antibody-drug conjugates and related methods.
CN107074879A (en) Novel cytotoxic molecule applied to cell-binding molecules drug conjugates
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
WO2021044208A8 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
WO2007134037A3 (en) Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
BRPI0513959A (en) antibodies directed against beta-amyloid peptide, their pharmaceutical compositions, kit and methods of manufacture thereof
AR046639A1 (en) ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
BRPI0514199A (en) method of effecting prophylaxis or treating a disease, pharmaceutical composition, monoclonal antibody, hybridoma cell, and method of screening an agent, humanizing monoclonal antibody 8a5 or monoclonal antibody 6h7 and producing a chimeric form of monoclonal antibody 8a5 or monoclonal antibody 6h7
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
MX2021010453A (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof.
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
WO2003015817A3 (en) Oral immunoglobulin treatment for inflammatory bowel disease
WO2002014343A8 (en) Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
AR045765A1 (en) MOLECULES OF UNION TO CD45 AND THERAPEUTIC USE
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
WO2023137399A3 (en) Inflammatory disease treatment using anti-tissue factor antibodies
BR112022019853A2 (en) IMMUNOCONJUGATE THAT SPECIFICALLY BINDS ENO-1, COMPOSITION FOR DIAGNOSING OR IMAGING CELLS OR TISSUE EXPRESSING ENO-1, PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF AN INFLAMMATORY DISEASE, METHOD FOR TREATMENT OF AN INFLAMMATORY DISEASE, AND USE OF THE IMMUNOCONJUGATE
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates
MX2022010945A (en) Therapeutic uses of macrocyclic compounds.